title: Features of ovarian cancer in Lynch syndrome (Review).
abstract: Lynch syndrome is a hereditary ovarian cancer with a prevalence of 0.9-2.7%. Lynch syndrome accounts for 10-15% of hereditary ovarian cancers, while hereditary breast and ovarian cancer syndrome accounts for 65-75% of these cancers. The lifetime risk for ovarian cancer in families with Lynch syndrome is ~8%, which is lower than colorectal and endometrial cancers, and ovarian cancer is not listed in the Amsterdam Criteria II. More than half of sporadic ovarian cancers are diagnosed in stage III or IV, but ≥80% of ovarian cancers in Lynch syndrome are diagnosed in stage I or II. Ovarian cancers in Lynch syndrome mostly have non-serous histology and different properties from those of sporadic ovarian cancers. A screening method for ovarian cancers in Lynch syndrome has yet to be established and clinical studies of prophylactic administration of oral contraceptives are not available. However, molecular profiles at the genetic level indicate that ovarian cancer in Lynch syndrome has a more favorable prognosis than sporadic ovarian cancer. Inhibitors of the phosphatidylinositol 3-kinase/mammalian target of the rapamycin pathway and anti-epidermal growth factor antibodies may have efficacy for the disease. To the best of our knowledge, this is the first review focusing on ovarian cancer in Lynch syndrome.
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-8582, Japan.
authors.forename: Kanako
authors.initials: K
authors.lastname: Nakamura
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-8582, Japan.
authors.forename: Kouji
authors.initials: K
authors.lastname: Banno
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-8582, Japan.
authors.forename: Megumi
authors.initials: M
authors.lastname: Yanokura
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-8582, Japan.
authors.forename: Miho
authors.initials: M
authors.lastname: Iida
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-8582, Japan.
authors.forename: Masataka
authors.initials: M
authors.lastname: Adachi
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-8582, Japan.
authors.forename: Kenta
authors.initials: K
authors.lastname: Masuda
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-8582, Japan.
authors.forename: Arisa
authors.initials: A
authors.lastname: Ueki
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-8582, Japan.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Kobayashi
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-8582, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Nomura
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-8582, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Hirasawa
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-8582, Japan.
authors.forename: Eiichiro
authors.initials: E
authors.lastname: Tominaga
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-8582, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Aoki
keywords: chemoprevention; lynch syndrome; ovarian cancer; risk-reducing surgery; surveillance